BioPharmSignal logoBioPharmSignal

Biotech News

Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma

Iovance Biotherapeutics, Inc. (IOVA)Iovance Biotherapeutics, Inc.Clinical readout

62.5% Confirmed Objective Response Rate (ORR) and 29.2% Complete Response (CR) Rate in Final Phase 2 Analysis Median Overall Survival (OS) Not Reached at More than 4 Years of Median Follow-up Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 Reinforces Ongoing

Related news

IOVAIovance Biotherapeutics, Inc.2026-10-26 11:00 EST

Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026

BMYBMYBristol-Myers Squibb Company2026-10-25 07:30 EST

BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

BMYBMYBristol-Myers Squibb Company2026-11-06 21:00 EST

Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions

IMCRImmunocore Holdings plc2026-11-06 17:00 EST

Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma

IOVAIovance Biotherapeutics, Inc.2026-10-19 11:00 EST

Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026

CRSPCRISPR Therapeutics2026-11-04 14:01 EST

CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition

RVMDRevolution Medicines2026-10-20 12:00 EST

Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer

IMCRImmunocore Holdings plc2026-10-29 13:00 EST

Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting

MGNXMacroGenics2026-10-26 11:06 EST

MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer

RVMDRevolution Medicines2026-10-23 11:30 EST

Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026

View all latest news

Iovance Biotherapeutics, Inc.

Tumor-Infiltrating Lymphocyte Therapy Iovance Biotherapeutics develops and commercializes autologous tumor-infiltrating lymphocyte therapies for solid tumors. Patient T cells are isolated from a tumor, expanded and reinfused following lymphodepletion. Amtagvi Amtagvi, or lifileucel, is approved in the United States for selected patients...

Recent company news

IOVAIovance Biotherapeutics, Inc.2026-11-05 12:00 EST

Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates

IOVAIovance Biotherapeutics, Inc.2026-10-29 11:00 EST

Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)

IOVAIovance Biotherapeutics, Inc.2026-10-28 23:00 EST

Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy

IOVAIovance Biotherapeutics, Inc.2026-10-27 11:00 EST

Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026

IOVAIovance Biotherapeutics, Inc.2026-10-26 11:00 EST

Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026

Stock data

Close
7.74 USD
Market cap
1.83B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States